Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study.
Administrative data
Clinic-based administration
Home-based administration
Immunoglobulin G
Intravenous
Real world evidence
Subcutaneous
Journal
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313
Informations de publication
Date de publication:
24 Nov 2022
24 Nov 2022
Historique:
received:
04
05
2022
accepted:
17
10
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
27
11
2022
Statut:
epublish
Résumé
Self-administered subcutaneous immunoglobulin G (SCIg) reduces nursing time and eliminates the need for treatment at ambulatory care clinics, as compared with clinic-based intravenously administered IgG (IVIg), and are therapeutically equivalent. Estimating the economic impact of self-administered SCIg versus clinic-administered IVIg therapy may guide treatment recommendations. A retrospective population-based cohort study using administrative data from Alberta was performed; those treated with IgG between April 1, 2012 and March 31, 2019 were included. Costs for medical laboratory staff and nursing time, as well as ambulatory care visits were considered. Univariate generalized linear model regression with gamma distribution and log link was used to compare cost ($CDN 2020) between SCIg and IVIg administration. Stratified analysis by age (≥ 18-years; < 18-years) was performed. Among 7,890 (6,148 adults; 1,742 children) individuals who received IgG, the average administration cost per patient-year of self-administered SCIg was $5,386 (95% confidence interval [CI] $5,039, $5,734) lower than clinic-administered IVIg; per patient-year cost of self-administered SCIg was $817 (95% CI $723, $912) versus $6,204 (95% CI $6,100, $6,308) for clinic-administered IVIg. The per patient-year cost of self-administered SCIg was $5,931 (95% CI $5,543, $6,319) lower among adults and $3,177 (95% CI $2,473, $3,882) lower among children compared with clinic-administered IVIg. An estimated $31.0 million (95% CI $29.0, $33.0) in cost savings to the health system would be realised if 80% of individuals switched from clinic-administered IVIg to self-administered SCIg. Self-administered SCIg is substantially less costly from a health care payer perspective in Canada. Within this type of health system, switching to self-administered SCIg has the potential to reduce overall health care costs, lessen nursing burden, and may increase clinic-based capacity for others.
Sections du résumé
BACKGROUND
BACKGROUND
Self-administered subcutaneous immunoglobulin G (SCIg) reduces nursing time and eliminates the need for treatment at ambulatory care clinics, as compared with clinic-based intravenously administered IgG (IVIg), and are therapeutically equivalent. Estimating the economic impact of self-administered SCIg versus clinic-administered IVIg therapy may guide treatment recommendations.
METHODS
METHODS
A retrospective population-based cohort study using administrative data from Alberta was performed; those treated with IgG between April 1, 2012 and March 31, 2019 were included. Costs for medical laboratory staff and nursing time, as well as ambulatory care visits were considered. Univariate generalized linear model regression with gamma distribution and log link was used to compare cost ($CDN 2020) between SCIg and IVIg administration. Stratified analysis by age (≥ 18-years; < 18-years) was performed.
RESULTS
RESULTS
Among 7,890 (6,148 adults; 1,742 children) individuals who received IgG, the average administration cost per patient-year of self-administered SCIg was $5,386 (95% confidence interval [CI] $5,039, $5,734) lower than clinic-administered IVIg; per patient-year cost of self-administered SCIg was $817 (95% CI $723, $912) versus $6,204 (95% CI $6,100, $6,308) for clinic-administered IVIg. The per patient-year cost of self-administered SCIg was $5,931 (95% CI $5,543, $6,319) lower among adults and $3,177 (95% CI $2,473, $3,882) lower among children compared with clinic-administered IVIg. An estimated $31.0 million (95% CI $29.0, $33.0) in cost savings to the health system would be realised if 80% of individuals switched from clinic-administered IVIg to self-administered SCIg.
CONCLUSIONS
CONCLUSIONS
Self-administered SCIg is substantially less costly from a health care payer perspective in Canada. Within this type of health system, switching to self-administered SCIg has the potential to reduce overall health care costs, lessen nursing burden, and may increase clinic-based capacity for others.
Identifiants
pubmed: 36434668
doi: 10.1186/s13223-022-00735-6
pii: 10.1186/s13223-022-00735-6
pmc: PMC9700869
doi:
Types de publication
Journal Article
Langues
eng
Pagination
99Informations de copyright
© 2022. The Author(s).
Références
Immunol Allergy Clin North Am. 2008 Nov;28(4):861-74, x
pubmed: 18940579
Transfus Med. 2013 Feb;23(1):55-60
pubmed: 23167310
P T. 2013 Dec;38(12):768-70
pubmed: 24391400
J Clin Immunol. 2012 Dec;32(6):1180-92
pubmed: 22730009
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Ann Allergy Asthma Immunol. 2018 Feb;120(2):195-199
pubmed: 29413344
J Allergy Clin Immunol. 2013 Feb;131(2):585-7.e1-3
pubmed: 23040368
Ont Health Technol Assess Ser. 2017 Nov 01;17(16):1-86
pubmed: 31210833
JAMA. 1995 Jun 21;273(23):1865-70
pubmed: 7776504
Allergy Asthma Clin Immunol. 2014 May 07;10(1):23
pubmed: 24872821
Transfusion. 2007 Nov;47(11):2072-80
pubmed: 17958537
Am Health Drug Benefits. 2019 Oct;12(6):294-304
pubmed: 31908713
Am J Health Syst Pharm. 2008 Oct 1;65(19):1815-24
pubmed: 18796422